1. Poland Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
BIOTON S.A.

BIOTON S.A.

GGPW:BIO
3.70
PLN
+0.00
(-0.13%)
-0.11EPS
340.02MMarket Cap
Nov 10Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
4.03
4.39
3.87
3.23
4.21
2.81
2.35
2.58
1.9
2.72
2.12
2.42
3.29
3.08
Basic EPS, GAAP
-0.08
0.04
-6.09
-0.33
-0.23
0.31
-1.48
0.4
0.03
0.02
0.03
-0.18
0.04
-0.11
Free Cash Flow per Basic Share
0.22
0.16
-0.05
-0.01
-0.19
-0.18
-0.08
0.43
-0.09
0.31
-0.05
0.29
0.11
-0.07
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
15.13
15.85
9.59
9.26
8.62
8.3
6.82
7.22
7.04
7.04
7.06
6.88
6.92
6.75
Tangible Book Value per Share
2.08
2.29
3.99
3.96
3.7
3.59
2.43
2.84
2.82
2.75
2.76
2.89
3.11
3.02
Basic Weighted Avg Shares
85
86
86
86
86
86
86
86
86
86
86
86
86
86
Sales/Revenue/Turnover
340
377
333
278
362
241
202
222
163
233
182
208
283
264
Operating Margin (%)
3.25
4.99
5.83
-6.17
1.09
-20.78
-7.89
23.96
7.74
11.16
-1.68
-2.46
5.12
-1.28
Depreciation Expense
30
34
37
35
33
29
32
32
32
34
35
36
38
39
Net Income, GAAP
-6
4
-523
-29
-20
26
-127
34
3
1
2
-16
3
-9
Effective Tax Rate (%)
95.57
44.53
- -
- -
- -
- -
- -
18.48
65.41
71.3
68.55
- -
56.67
- -
Profit Margin (%)
-1.89
0.97
-157.22
-10.29
-5.57
10.89
-62.71
15.29
1.77
0.61
1.25
-7.54
1.2
-3.52
Working Capital
10
67
23
23
-6
-23
-60
-6
9
12
1
11
42
31
LT Debt
112
98
59
48
23
18
48
39
29
19
13
14
21
20
Total Equity
1,385
1,446
807
788
735
713
585
620
605
604
606
591
594
580
Return on Invested Capital (%)
0.05
0.75
- -
- -
- -
- -
- -
5.43
0.68
0.87
0.71
- -
0.88
- -
Return on Capital (%)
-0.37
0.89
- -
- -
- -
- -
- -
5.28
0.62
0.53
0.72
- -
0.86
- -
Return on Common Equity (%)
-0.51
0.28
-47.88
-3.53
-2.62
3.61
-19.52
5.63
0.47
0.24
0.38
-2.62
0.57
-1.6

Capital Structure

PLN

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
36
37
47
LT Borrowings
7
7
6
LT Finance Leases
14
15
14
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
86
86
86
Market Capitalization
331
371
340

Working Capital

PLN

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
145
152
161
Cash, Cash Equivalents & STI
8
3
1
Accounts Receivable, Net
29
27
32
Inventories
95
105
110
Total Current Liabilities
103
112
130
Payables & Accruals
- -
- -
- -
ST Debt
36
37
47
Deferred Revenue
- -
- -
- -

Growth Rates

PLN

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-2.82%
-0.83%
0.58%
Free Cash Flow
-102.4%
-282.44%
-61.98%
Net Income, GAAP
-205.56%
-198.4%
-121.67%
Sales/Revenue/Turnover
1.88%
8.96%
35.98%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
37
51
42
78
208
2025
66
80
- -
64
283
2026
49
71
- -
- -
- -

Quarterly Earnings Per Share

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.06
-0.03
-0.04
-0.05
-0.18
2025
-0.07
0.04
- -
0.02
0.04
2026
-0.06
-0.11
- -
- -
- -

Quarterly Dividends Per Share

PLN

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jeremy Launders
Full Time Employees
361
Sector
Health technology
Industry
Pharmaceuticals: major
Address
ul. Poznanska 12 Warsaw MZ Poland 05-850
IPO Date
Mar 16, 2005
Website
bioton.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Bioton SA (BIO.WA) is a Poland-based biotechnology company that develops, manufactures, markets and sells recombinant human insulin and related pharmaceutical products; provides contract development and manufacturing organization (CDMO) services including process development, analytical testing, technology transfer and GMP-compliant production of recombinant proteins and peptides; and offers innovative gastroenterological foods for special medical purposes (FSMP) alongside diabetes care solutions such as insulin analogs, oral antidiabetics, medical devices and digital health platforms. Founded in 1989 and headquartered in Ożarów Mazowiecki near Warsaw, the company operates primarily in Poland with exports to 35 countries including China, Russia, Thailand and Egypt, positioning it as a leader in the Polish diabetes market and among the world's top eight producers of recombinant human insulin. In June 2025, Bioton signed a memorandum of understanding with The Heart to collaborate on R&D pipeline expansion in biotechnology production, diabetology and gut health innovations; in October 2024, it secured a production agreement with a global pharmaceutical company for recombinant human insulin; and it continues to invest in modernizing its Macierzysz manufacturing site while enhancing CDMO capabilities through scale-down model laboratories and QbD-compliant processes.